Users of Zepbound or Mounjaro Had Lower Blood Pressure in Studynews2024-02-05T16:10:45+00:00February 5th, 2024|The New York Times|
6 Reasons That It’s Hard to Get Your Wegovy and Other Weight-Loss Prescriptionsnews2024-02-02T20:20:57+00:00February 2nd, 2024|The New York Times|
Buried in Wegovy Costs, North Carolina Will Stop Paying for Obesity Drugsnews2024-01-26T18:52:40+00:00January 26th, 2024|The New York Times|
Eli Lilly, Maker of Mounjaro and Zepbound, Wades Into Telehealthnews2024-01-05T21:20:53+00:00January 5th, 2024|The New York Times|
Can Ozempic and Weight Loss Drugs Treat Other Diseases?news2023-12-20T16:09:05+00:00December 20th, 2023|The New York Times|
Drugs like Wegovy Can Fix Teenage Obesity, but Young People Don’t Get Themnews2023-12-11T18:17:26+00:00December 11th, 2023|The New York Times|
Zepbound, el nuevo medicamento aprobado por la FDA para perder pesonews2023-11-13T10:01:53+00:00November 13th, 2023|The New York Times|
Weight Loss Drug Wegovy Can Cut Heart Attack Risk for Some, Study Showsnews2023-11-12T05:20:43+00:00November 12th, 2023|The New York Times|
F.D.A. Approves New Obesity Drug Tirzepatide That Will Compete With Wegovynews2023-11-09T01:02:09+00:00November 9th, 2023|The New York Times|
